Skip to content

Fighting to Preserve the Benefits of the 340B Program

Facebook page opens in new windowX page opens in new windowLinkedin page opens in new windowMail page opens in new window
RWC-340B
Ryan White Clinics for 340B Access
RWC-340B
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • Get The Facts
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
  • News
  • About Us
    • RWC-340B Principles
Search:
  • Members
    • RWC-340B Members
    • Become a Member
  • Benefactors
    • Meet Our Benefactors
    • Benefactor Application
  • Expert Advice
    • Outline of Technical Assistance
    • Peer-to-Peer Mentoring
  • Advocacy
    • Get The Facts
    • TAKE ACTION
    • Congressional Advocacy
    • Regulatory Advocacy
    • State Advocacy
    • Litigation
  • Issues
    • Contract Pharmacy
    • Discriminatory Reimbursement Toolkit
    • Carve-out Toolkit
    • PrEP Toolkit
    • COVID-19 Toolkit
    • RWC-340B Key Research
  • Events
    • Conferences
  • News
  • About Us
    • RWC-340B Principles

RWC340B Logo Square 1000 × 1000 px

Boehringer Ingelheim Broadens Contract Pharmacy Restrictions

RWC-340BBy Amber TynanJune 27, 2023

Boehringer Ingelheim (BI) is among the 23 manufacturers that currently restrict contract pharmacy relationships with covered entities. It is also the 16th manufacturer to broaden its restrictions on contract pharmacies following the…

RWC340B Logo Square 1000 × 1000 px

Updated Chart: Pharmaceutical Manufacturer 340B Price Restriction Policies and Exemptions Summary

RWC-340BBy Amber TynanJune 26, 2023

View Here: Pharmaceutical Manufacturer 340B Price Restriction Policies and Exemptions Summary 6.21.23

RWC340B Logo Square 1000 × 1000 px

National Ryan White Clinic Organization Fires Back at Gilead-Funded “Study” Riddled with Inaccuracies, Faulty Assumptions, and Profit-Centered Analysis

RWC-340BBy Amber TynanJune 20, 2023

  PRESS STATEMENT: FOR IMMEDIATE RELEASE June 20, 2023   National Ryan White Clinic Organization Fires Back at Gilead-Funded “Study” Riddled with Inaccuracies, Faulty Assumptions, and Profit-Centered Analysis   The…

RWC340B Logo Square 1000 × 1000 px

Novo Nordisk Tightens Restrictions on 340B Drugs Dispensed by Contract Pharmacies; Organon Becomes the 22nd Manufacturer to Issue Restrictions

RWC-340BBy Amber TynanJune 6, 2023

Novo Nordisk Tightens Restrictions on 340B Drugs Dispensed by Contract Pharmacies; Organon Becomes the 22nd Manufacturer to Issue Restrictions On June 1, 2023, Novo Nordisk and Organon each announced restrictions…

                                                                            © 2021 Ryan White Clinics for 340B Access. RWC-340B is a 501(c)(4) non-profit corporation.
Go to Top
Translate »
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset